We are live on ! Find out more

Biodesix

BDSX

Market cap $245M

23.25 USD

-1.47

5.95%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

23.72

+0.47

2.02%

1 day

-5.95%

5 days

7.94%

1 month

-22.06%

3 months

8.95%

6 months

111.75%

Year to date

259.91%

1 year

253.88%

5 years

-85.08%

10 years

-90.93%

About: Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Employees: 334

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 45.5%

Neutral 50%

Negative 4.5%

Zacks Investment Research

All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy

Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy

Zacks Investment Research

Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should Know

Biodesix (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should Know

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Zacks Investment Research

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Biodesix: Growing Fast While Trading Below Many Diagnostics Peers

Biodesix is gaining momentum in lung diagnostics, with >30% revenue growth and accelerating test volumes. BDSX boasts 80%+ gross margins and improving operating leverage, supporting a credible path to profitability despite ongoing cash burn. The stock trades at a discounted EV/Sales multiple versus peers, despite industry-leading gross margins and robust clinical evidence.

Biodesix: Growing Fast While Trading Below Many Diagnostics Peers

See News Rankings

Price charts implemented using Lightweight Charts™